<DOC>
	<DOCNO>NCT02269319</DOCNO>
	<brief_summary>The purpose study determine whether MRX-I safe effective Linezolid treatment adult patient acute bacterial skin skin structure infection</brief_summary>
	<brief_title>MRX-I Versus Linezolid Treatment Acute Bacterial Skin Skin Structure Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Patients systemic sign infection diagnose acute bacterial skin skin structure infection ( ABSSSI ) Diagnosed Cellulitis/ erysipelas , major cutaneous abscess , wound infection Uncomplicated skin infection Severe sepsis septic shock ABSSSI solely due gramnegative pathogen Prior systemic antibiotic within 96 hour randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABSSSI</keyword>
	<keyword>MRX-I</keyword>
	<keyword>Acute Bacterial Skin Skin Structure Infections</keyword>
</DOC>